肺癌筛查CT检出的气道结节:Lung-RADS 1.1版与2022版分类比较
本回顾性研究纳入2015至2021年间在本医疗网络内接受肺癌筛查CT并报告气道或支气管内结节的全部174例患者,由一名经过专科培训的心胸放射科医师复习CT图像,比较Lung-RADS 1.1版与2022版对气道结节的分类效能。结果显示2022版在保持敏感度91%不变的情况下,特异度由50%提高至82%(P < .001),减少了假阳性筛查CT检查。
要点
- 气管和主支气管的气道结节均为良性,肺叶和段支气管结节肺癌风险最高(分别为17.2%和11.1%)。
- 12个亚段气道结节中阻塞性者3个(25%)为恶性、9个(75%)为良性;非阻塞性形态、气道依赖部位、内部含气或液性衰减的结节均为良性。
- 临床报告Lung-RADS阳性患者92例中仅10例(10.9%)为癌;2022版较1.1版特异度提高(82% vs 50%,P < .001),敏感度均为91%。
核心结论
- 与1.1版相比,Lung-RADS 2022版减少了假阳性筛查CT检查,同时仍能识别恶性气道结节。
研究设计与样本
- 回顾性研究,纳入2015至2021年间在本医疗网络内接受肺癌筛查CT并报告气道或支气管内结节的全部174例患者。
关键影像表现/征象
- 气管和主支气管的气道结节均为良性,肺叶和段支气管气道结节肺癌风险最高(分别为17.2%和11.1%)。
- 92例临床报告Lung-RADS阳性的患者中仅10例(10.9%)为癌。
- 12个亚段气道结节中阻塞性者3个(25%)为恶性、9个(75%)为良性。
- 非阻塞性形态、气道依赖部位、内部含气或液性衰减的结节均为良性。
诊断标准与关键数值
- Lung-RADS 2022版检测恶性气道结节的敏感度为91%,特异度为82%。
- Lung-RADS 1.1版检测恶性气道结节的敏感度为91%,特异度为50%。
- 2022版较1.1版特异度提高(82% vs 50%,P < .001),敏感度均为91%。
临床应用与阅片要点
- 阅片时应注意气道结节的部位:气管和主支气管结节均为良性,肺叶和段支气管结节肺癌风险最高(分别为17.2%和11.1%)。
- 亚段气道结节中阻塞性者25%(3/12)为恶性,非阻塞性形态、气道依赖部位、内部含气或液性衰减的结节均为良性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To compare the Lung Imaging Reporting and Data System (Lung-RADS) version 1.1 with version 2022 classification of airway nodules detected at lung cancer screening CT examinations. Materials and Methods This retrospective study included all patients who underwent a lung cancer screening CT examination in the authors' health care network between 2015 and 2021 with a reported airway or endobronchial nodule. A fellowship-trained cardiothoracic radiologist reviewed these CT images and characterized the airway nodules by size, location, multiplicity, morphology, dependent portions of airway, internal air, fluid attenuation, distal changes, outcome at follow-up, and final pathologic diagnosis, if malignant. Sensitivity and specificity of Lung-RADS version 1.1 in detecting malignant nodules were compared with those of Lung-RADS version 2022 using the McNemar test. Results A total of 174 patients were included. Of these, 163 (94%) had airway nodules that were deemed benign, while 11 (6%) had malignant nodules. Airway nodules in the trachea and mainstem bronchi were all benign, while lobar and segmental airway nodules had the highest risk for lung cancer (17.2% and 11.1%, respectively). Of the 12 subsegmental airway nodules that were obstructive, three (25%) were malignant and nine (75%) were benign. Nodules with nonobstructive morphologies, dependent portions of airway, internal air, or fluid attenuation were all benign. Only 10 of the 92 (10.9%) patients with positive Lung-RADS by clinical report had cancer. Lung-RADS version 2022 resulted in higher specificity than version 1.1 (82% vs 50%, P < .001), without sacrificing sensitivity (91% for both). Conclusion Compared with the previous version, Lung-RADS version 2022 reduced the number of false-positive screening CT examinations while still identifying malignant airway nodules. Keywords: CT, Lung, Primary Neoplasms, Pulmonary, Lung Cancer Screening, Lung-RADS, Nodule Risk, Airway Nodule, Endobronchial Nodule © RSNA, 2024.
引用
- DeSimone AK, Byrne SC, Hammer MM, et al. Comparison of Lung-RADS Version 1.1 and Lung-RADS Version 2022 in Classifying Airway Nodules Detected at Lung Cancer Screening CT. Radiol Cardiothorac Imaging. 2024. PMID: 38300115. doi:10.1148/ryct.230149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。